Introduction
Platelet activation is a complex network of interdependent biochemical processes through which platelets undergo a sequence of responses: shape change, aggregation, and secretion. All of these responses can be induced by a number of physiological agonists such as thrombin, ADP, platelet-activating factor and thromboxane A 2 (TXA 2 ) 1 (1) . TXA 2 is a major arachidonic acid metabolite in platelets that binds to the specific membrane receptor to initiate these processes (2) . The TXA 2 receptor is linked via a guanine nucleotide-binding protein (G protein) of the G q class to phospholipase C (PLC), which hydrolyses phosphoinositides to the two potent stimulatory second messengers inositol 1,4,5-triphosphate (IP 3 ) and diacylglycerol (3, 4) . These molecules affect divergent pathways of platelet activation; IP 3 causes increases in cytoplasmic free calcium and diacylglycerol causes activation of protein kinase C. However, whether this pathway contributes to all of the TXA 2 -induced platelet responses remains undefined. Some studies using the radiolabeled TXA 2 analogs as ligands demonstrated two classes of binding sites in platelets, and indicated that they might represent the receptor subtypes (5) (6) (7) (8) . They further suggested that the two putative subtypes of the receptor may independently mediate shape change and aggregation (8, 9) . This suggestion has been supported by the reports that platelet shape change and aggregation can be differentiated by several TXA 2 analogs. For example, in some species, the TXA 2 agonist U46619 induces platelet shape change and an increase in calcium without aggregation (10) . In addition, the TXA 2 analog S-145 prevents aggregation and secretion by U46619 but itself induces shape change (11) . One model consistent with these observations is that the TXA 2 receptormediated signaling consists of two separate receptor-effector systems mediating distinct functional responses; one linked to PLC activation resulting in platelet aggregation and secretion, and the other mediating an increase in cytosolic calcium and platelet shape change (12) .
We have recently identified Arg 60 to Leu mutation in the first cytoplasmic loop of the TXA 2 receptor in a bleeding disorder characterized by defective platelet aggregation responses to TXA 2 and its analogs (13) . The platelets of the patients with this mutation were impaired in PLC activation. Consistently, the Arg 60 to Leu mutant of TXR ␣ expressed in cultured cells exhibited impaired agonist-induced PLC activation. Their platelets, however, exhibited shape change and phospholipase A 2 (PLA 2 ) activation when stimulated by a TXA 2 agonist (14, 15). These findings favor the hypothesis that shape change and PLA 2 activation are not mediated by PLC activation but by other pathways independent of PLC activation and not affected by this mutation. A cDNA encoding a TXA 2 receptor has initially been cloned from human placenta and the deduced 343-amino acid sequence indicates that it belongs to the superfamily of G protein-coupled receptors (16). Recently, a cDNA encoding a receptor isoform of 407 amino acids has been isolated from human endothelium (17 two isoforms, here referred to as TXR ␣ and TXR ␤ , are generated by alternative splicing from a single gene and differ only in their carboxyl-terminal domains; the 15 amino acid sequence in the carboxyl end of TXR ␣ is replaced by a 79-amino acid sequence in TXR ␤ . The existence of multiple isoforms could account for the separate effector systems linked to the TXA 2 receptor, provided both isoforms are present in platelets and divergent in their signaling pathways.
Here we report the identification of two isoforms of the human TXA 2 receptor in platelets. The two isoforms expressed in cultured cells showed the same ligand binding characteristics and agonist-induced activation of PLC but distinct effects on adenylyl cyclase activity; TXR ␣ activated adenylyl cyclase, while TXR ␤ inhibited it. Since the patients with the Arg 60 to Leu mutation of the TXA 2 receptor showed some of the TXA 2 -induced platelet responses, we have examined the effects of this mutation on these pathways to explore their possible involvement in those responses. We show that the Arg 60 to Leu mutation selectively impairs the pathways linked to PLC activation and to adenylyl cyclase stimulation but not that linked to adenylyl cyclase inhibition. It is, therefore, possible that the pathway linked to adenylyl cyclase inhibition is involved in the platelet responses remaining unaffected in these patients.
Methods
Materials. 9,11-epithio-11,12-methano-TXA 2 (STA 2 ) was a generous gift from Ono Pharmaceuticals Co. Ltd. (Osaka, Japan). 5Z-7- . All other materials were obtained from the sources as described previously (13) .
Amplification of platelet mRNA. Total RNA was extracted from platelets by the acid guanidium-phenol-chloroform method (18) . 1 g of total RNA was reverse-transcribed (RT) in a volume of 20 l as described previously (19) . For a control, reactions were carried out under the same conditions without reverse transcriptase. 2 l of the reaction mixture was used for amplification by polymerase chain reaction (PCR) in a final volume of 20 l, containing 50 mM KCl, 10 mM Tris-HCl (pH 8.8), 1.5 mM MgCl 2 , 0.1% Triton X-100, 10% dimethylsulfoxide, 0.25 mM dNTPs, 1 U Taq Polymerase (Wako Pure Chemical Industries Ltd., Osaka, Japan), and 20 pmol of each primer. After denaturation at 94 Њ C for 2 min, 35 cycles (94 Њ C for 1 min, 62 Њ C for 1 min, 72 Њ C for 1.5 min) were followed by a final elongation step for 3.5 min at 72 Њ C. Primers used are based on the sequences of the TXA 2 receptor isolated from placenta (16). One pair of primers include TX30 (5 Ј -CCGCCATGGCCTCAGAGCGCTAC-3 Ј ) corresponding to nucleotides (nt) 371-393, as numbered in the published sequence (16), and 3T4 (5 Ј -GGGGTGCCCGCGTTTCACAT-3 Ј ; nt 1884-1903). Other pairs include 7S1 (5 Ј -CTGCTCATCTACTTG-CGCGT-3 Ј ; nt 868-887) and 3T4, or 7S1 and 3T2 (5 Ј -CAGGGTCAA-AGAGCATGCAA-3 Ј ; nt 1787-1806). PCR products were electrophoresed, excised, purified using Geneclean II (Bio 101 Inc., Vista, CA), and blunt-end-ligated to pBluescript II SK ϩ (Stratagene, La Jolla, CA). Plasmid subclones were sequenced by the dideoxy chain termination method.
Genomic PCR. Genomic DNA was prepared from white blood cells of the patient T.T. (13) as described (20). A 1146 bp fragment that includes the portion encoding peptide-␤ was amplified by PCR, using primers I2 (5 Ј -GTCCAGGCTGACAGCTCTCC-3 Ј ) corresponding to intronic nt -29 to -10 upstream from the second coding exon (21) and 3T4. PCR was done as described in RT-PCR except that 0.1 g genomic DNA was used instead of RT reaction mixture as a template. PCR products were subcloned and sequenced.
Expression of wild-type and mutant TXA 2 receptor isoforms. For transient expression, cDNAs encoding the two isoforms were inserted into the pCMX expression vector under the control of the cytomegalovirus promoter (22) and COS-m6 were transfected in 15-cm dishes with 25 g of plasmid DNA by calcium phosphate precipitation (23) . The cells were grown in DME with 10% fetal calf serum and harvested at 72 h after transfection for ligand binding assays or at 24 h to be trypsinized and plated in 6-well plates for phosphatidylinositol (PI) assay. For stable expression, cDNAs encoding the wild-type and mutant isoforms were inserted into the mammalian expression vector pEF-BOS (24) with a blasticidin S-resistance marker (Funakoshi Co. Ltd.) and introduced into Chinese hamster ovary (CHO) cells by the calcium phosphate method. Stable transformants were cloned by selection in the ␣ -modified minimal essential medium containing 10% fetal calf serum and 15 ng/ml blasticidin S (Funakoshi Co. Ltd.).
Ligand binding studies. Tansfected COS-m6 cells or CHO cells were cultured in 15 cm dishes to confluency and harvested as described previously (25) . Cells were washed once and suspended at 1 ϫ 10 7 cells/ml in a buffer containing 20 mM Hepes (pH 7.4), 140 mM NaCl, 5 mM KCl, 5 mM MgCl 2 . Binding assays were performed essentially as described (26) . Briefly, cells (100 l) were incubated in a total volume of 200 l at 30ЊC for 1 h. In the [ 3 H]S-145 saturation experiments, nine different concentrations of the radioligand (0.125-32 nM) were used. In the displacement experiments, 1 nM of [ 3 H]S-145 and different concentrations of the unlabeled competitors were employed. The reaction was terminated by the addition of 4 ml of icecold 10 mM Tris (pH 7.4) and immediate vacuum filtration through GF/C filters (Whatman International Ltd., Maidstone, England) followed by four additional 4-ml washes with the same buffer. The radioactivity on the filter was measured by scintillation counting. Nonspecific binding was determined in the presence of a 1,000-fold excess of unlabeled S-145.
Measurement of PI hydrolysis. Transfected COS-m6 cells or CHO cells were cultured in 6-well plates to 90% confluency in the medium described above and then incubated for 20 h in inositol-free DME with 10% dialyzed fetal calf serum containing 1 Ci/ml myo-[2-
3 H]inositol. The cells were washed with Hepes-buffered saline (HBS) and preincubated with 10 mM LiCl in HBS at 37ЊC for 10 min. Then various concentrations of STA 2 were added to each medium. After 5 or 30 min incubation, the medium was removed and the reaction was terminated by 1 ml of 5% trichloroacetic acid. The generation of IP 3 or total inositol phosphate was measured as described (27) .
cAMP assays. CHO cells stably expressing wild-type or mutant isoforms were cultured in 24-well plates and treated with or without 100 ng/ml pertussis toxin for 12 h. They were then washed once with HBS and preincubated for 10 min in HBS containing 0.1 mM RO-20-1724 at 37ЊC. Cells were then stimulated for 10 min with I-BOP at the indicated concentrations with or without 1 M forskolin. The reaction was terminated by the addition of an equal volume (0.5 ml) of 10% trichloroacetic acid. Quantification of cAMP was performed by a radioimmunoassay using an Amersham cAMP assay kit.
Results
Identification of two isoforms of the human TXA 2 receptor in platelets. cDNAs encoding two isoforms of the human TXA 2 receptor have already been cloned (16, 17) . These are schematically represented in Fig. 1 B. Comparison of two cDNAs revealed that TXR␤ has a deletion of a 659-bp sequence that comprises the distal portion of the cytoplasmic carboxyl tail and the following 3Ј untranslated region of TXR␣. Deletion of this sequence results in another reading frame downstream in TXR␤. Consequently, a 15 amino acid carboxyl-terminal sequence of TXR␣ (peptide-␣) is replaced with a new 79 amino acid sequence (peptide-␤) in the carboxyl end of TXR␤ ( Fig. 1  C) . Peptide-␣ contains four serine and threonine residues as potential phosphorylation sites, whereas peptide-␤ contains 14 residues. To determine whether the two receptor isoforms exist in human platelets, RT-PCR was carried out. Two fragments were amplified using a sense primer TX30 located in the third transmembrane domain and an antisense primer 3T4 in the 3Ј untranslated domain shared by the two isoforms ( Fig. 1  A, lane 1) . The amplification of these fragments depended strictly on cDNA synthesis, indicating that the fragments were derived from RNA and not from contaminated genomic DNA. Sequence analyses confirmed that the larger band corresponds to TXR␣ and the smaller band TXR␤. Additional PCR reactions using different pairs of primers (7S1ϩ3T4 and 7S1ϩ3T2) each yielded two bands of the expected size ( Fig. 1  A, lanes 2 and 3) , further confirming the presence of the two isoforms in platelets.
Ligand binding characteristics of the two TXA 2 receptor isoforms. To investigate functional differences between the two isoforms, TXR␣ and TXR␤ were transiently expressed in COS-m6 cells or stably expressed in CHO cells. The two isoforms expressed in CHO cells displayed indistinguishable, high-affinity binding of the TXA 2 receptor antagonist [ 3 H]S-145 with a K d value of 2.1 nM for both TXR␣ and TXR␤ (Fig.  2 A) . Scatchard analyses using [ 3 H]S-145 revealed a single class of binding sites on both receptor isoforms. Similar results were obtained on transfected COS-m6 cells (data not shown). Because previous studies using I-BOP, a TXA 2 agonist, and GR32191, a TXA 2 antagonist, detected two classes of binding sites in platelets (8, 12) , binding of these ligands to the two isoforms were studied by testing their abilities to displace specific [ 3 H]S-145 binding. I-BOP displaced specific [ 3 H]S-145 binding to the two isoforms similarly (Fig. 2 B) . GR32191 also showed similar displacement for the two isoforms (Fig. 2 C) . Furthermore, GR32191, which identified reversible and irreversible binding sites in platelets (12), bound only irreversibly to both isoforms (data not shown). Thus, the two isoforms at least under the present experimental conditions do not correspond to the subtypes shown previously in platelets.
PLC activation by the two TXA 2 receptor isoforms. We next investigated whether the different carboxyl-terminal tails affect the PLC activation. Untransfected COS-m6 cells did not show any significant increase in inositol phosphate production to the TXA 2 agonist STA 2 (data not shown). Stimulation of cells expressing TXR␣ or TXR␤ by STA 2 induced an increase in inositol phosphate production with almost the same concentration-response curves (Fig. 3 ). Since we had previously shown that the Arg 60 to Leu mutation of TXR␣ impairs its agonist-induced activation of PLC, we asked whether this mutation also affects PLC activation mediated by TXR␤. Stable transformants expressing a similar number of wild-type or mutant TXR␤ were chosen for this experiment. Mutant TXR␤ exhibited an unaltered binding affinity for [ 3 H]S-145, compared to that of wild-type TXR␤ (Fig. 4 A) . When the two cell lines were examined for the activation of PLC, mutant TXR␤ was found to be impaired in its ability to produce agonistinduced PI hydrolysis ( Fig. 4 B) . These results indicate that the mutation impairs PLC activation both in TXR␣ and TXR␤. Thus, the Arg 60 in the first cytoplasmic loop appears to be essential for PLC activation.
Activation and inhibition of adenylyl cyclase by the two TXA 2 receptor isoforms. Previous studies have shown possible involvement of the adenylyl cyclase pathway in TXA 2 -mediated platelet responses, although the results are conflicting (28). Therefore, we examined effects of the difference of the carboxyl-terminal tail on adenylyl cyclase activation in cells expressing the two isoforms. As shown in Fig. 5 , I-BOP increased the level of cAMP in cells expressing TXR␣ in a concentration-dependent fashion above 10 nM, while no increase was . STA 2 -induced PLC activation in COS-m6 cells expressing the two TXA 2 receptor isoforms. COS-m6 cells transiently expressing TXR␣ (᭹) or TXR␤ (᭺) were incubated with STA 2 for 30 min and total inositol phosphate production was measured. Both isoforms are expressed in a similar number (190.1 pmol and 145.7 pmol / 1 ϫ 10 6 cells for TXR␣ and TXR␤, respectively). The data are presented as fold increases, where the values from the cells in the absence of STA 2 were chosen as the reference values. Data points are meanϮSE from 3 replicate wells from a single experiment. Where not shown, an SE bar is smaller than the symbol. The results were independently confirmed in two additional experiments. The EC 50 values for activation through TXR␣ and TXR␤ were 2.3 and 3.9 nM, respectively. found in those expressing TXR␤. We next examined whether the two isoforms can inhibit adenylyl cyclase. I-BOP inhibited the forskolin-induced cAMP generation in cells expressing TXR␤ but not in cells expressing TXR␣ ( Fig. 6 A) . This inhibition was sensitive to pertussis toxin treatment ( Fig. 6 C) , suggesting that it was mediated by the interaction of the receptor with G i /G o . Since pertussis toxin did not affect adenylyl cyclase stimulation by TXR␣ (data not shown), it seems that each isoform couples to a separate G protein in addition to a common G protein of the G q class.
Effects of the Arg 60 to Leu mutation on adenylyl cyclase activity. The finding that the TXA 2 receptor mediates pathways other than that linked to PLC led us to examine the effect of the Arg 60 to Leu mutation on these pathways, since the patients with this mutation show some platelet responses such as shape change and PLA 2 activation despite the defective activation of PLC when stimulated by a TXA 2 agonist. Before ad-dressing this question, we examined the genomic sequence corresponding to peptide-␤, that had not been analyzed in our previous study (13) , by genomic PCR in one of the patients, and confirmed that it bears no mutation. The Arg 60 to Leu mutation, which had been shown to impair PLC activation by TXR␣, also impaired adenylyl cyclase activation by this isoform ( Fig. 5 ). In contrast, as shown in Fig. 6 B, the mutant TXR␤ was capable of inhibiting adenylyl cyclase above the I-BOP concentration of 1 pM. This inhibitory effect was also sensitive to pertussis toxin treatment ( Fig. 6 C) . Taken together, the Arg 60 to Leu mutation affects the pathways linked to PLC activation and to adenylyl cyclase stimulation but not that linked to adenylyl cyclase inhibition. The existence of a pathway which is not affected by the mutation may be related to the partial response to TXA 2 in these patients.
Discussion
We have shown here that the two isoforms of the human TXA 2 receptor exist in platelets and that these isoforms mediate distinctive spectra of transduction pathways. Although the two isoforms similarly activated PLC, they differently regulated adenylyl cyclase activity; TXR␣ activated adenylyl cyclase, while TXR␤ inhibited it. Previous studies using some TXA 2 analogs identified two classes of binding sites in platelets and suggested the possibility that the receptor subtypes corresponding to these two classes are present and mediate separate functional responses of platelets. The presence of the two TXA 2 receptor isoforms in platelets first led us to compare their binding properties in relation to these studies. However, the expression studies in CHO cells and COS cells revealed no difference between the two; both I-BOP and GR32191 displaced specific [ 3 H]S-145 binding to the isoforms similarly, and GR32191 irreversibly bound to both isoforms. These results suggest that the two isoforms do not correspond to the two and mutant (᭡) TXR␤. CHO cells were incubated with STA 2 for 5 min and IP 3 production was measured. Data points are meanϮSE from three replicate wells from a single experiment. The results were independently confirmed in two additional experiments. The data are presented as fold increases, where the values from the cells in the absence of STA 2 were chosen as the reference values. Figure 5 . Adenylyl cyclase stimulation by wild-type and mutant TXR␣. CHO cells expressing TXR␣ (᭹), TXR␤ (᭺) or the Arg 60 to Leu mutant of TXR␣ (᭡) were incubated with various concentrations of I-BOP and the cAMP contents in the cells were measured as described in Methods. Data points are meanϮSE from 3 replicate wells from a single experiment. The results were independently confirmed in 2 additional experiments. The EC 50 value for activation through TXR␣ was 17 nM. classes of binding sites for some ligands found in intact platelets, unless they behave differently in platelets.
The identification of the pathway linked to adenylyl cyclase inhibition made us to wonder how this pathway is involved in TXA 2 -induced platelet responses. Both PLC activation and inhibition of adenylyl cyclase can lead to platelet activation. Given the lower concentrations required for adenylyl cyclase inhibition than for PLC activation, the two pathways might act independently rather than synergistically. We have found that they are distinguished by the effects of the Arg 60 to Leu mutation; PLC activation is attenuated by this mutation, whereas adenylyl cyclase inhibition is not. This mutation has been identified in a bleeding disorder characterized by defective platelet aggregation responses to TXA 2 and its agonists (13) . Previous study demonstrated that despite the impaired activation of PLC, the patients' platelets showed shape change (14) and PLA 2 activation (15), implying the existence of the pathways leading to these responses that are not affected by the mutation. As our studies showed that the inhibition of adenylyl cyclase is unaffected by the mutation, the pathway represented by this parameter might be implicated in shape change and PLA 2 activation. This pathway appears to be mediated by G i /G o because it is sensitive to pertussis toxin treatment. This is in accordance with our previous finding that the purified TXA 2 receptor is functionally reconstituted with both G i2 and G q in phospholipid vesicles (29) . Consistent with the idea that this G i /G o -linked pathway is involved in PLA 2 activation, TXA 2 stimulates mitogen-activated protein kinase via G i in some types of cells and activates PLA 2 (30, 31) . Thus, the present study suggests an intriguing possibility that the TXA 2 receptor isoforms separately mediate different kinds of activation responses in human platelets, although we cannot completely exclude the possibilities that other effector systems linked to the mutated receptor or those mediated by other receptor(s) than the mutated receptor evoke these responses.
Our experiments have also shown stimulation of adenylyl cyclase by one isoform of the TXA 2 receptor. Ishikawa and Ogawa (32) previously found that STA 2 elevated cAMP level in platelets at high concentrations to cause the inhibitory effect on aggregation. Based on this finding, they speculated that this pathway could negatively regulate platelet activation to attenuate or terminate responses. However, the stimulation they observed was not suppressed by a TXA 2 antagonist, ONO-3708. Because ONO-3708 completely displaced the radioligand binding to the cloned TXA 2 receptor (16), it is doubtful that the stimulation observed by these authors is mediated by the TXA 2 receptor we discuss here. Given the fact that stimulation of adenylyl cyclase is observed at relatively high agonist concentrations, the physiological significance of this pathway remains unclear.
Production of multiple isoforms by alternative splicing has been reported in G protein-coupled receptor family (33) (34) (35) (36) (37) (38) . Two regions of divergence that result from alternative splicing have been identified: the third cytoplasmic loop and the carboxyl-terminal tail. Those that have alternatively-spliced carboxyl tails include several members: the neurokinin-1 receptor (36), the prostaglandin E receptor EP 3 subtype (37), the monocyte chemoattractant protein-1 receptor (38) , and the TXA 2 receptor. Alternative splicing of the EP 3 receptor creates isoforms which exhibit distinct functional properties, including different efficiency in activation of a G protein (37) , different specificity in coupling to G proteins (39) and different sensitiv- Figure 6 . Adenylyl cyclase inhibition by wild-type and mutant TXR␤. (A and B) I-BOP-induced inhibition of forskolin-induced cAMP accumulation in CHO cells expressing TXR␣ (᭹), TXR␤ (᭺) or the Arg 60 to Leu mutant of TXR␤ (᭡). Cells were incubated with 1 M forskolin and various concentrations of I-BOP and the cAMP contents were measured. The data are presented as percentages of the control values obtained from the forskolin-stimulated cells in the absence of I-BOP. Data points are meanϮSE from three replicate wells from a single experiment. The results were independently confirmed in 2 additional experiments. The EC 50 values for activation through wild type and Arg 60 to Leu mutant of TXR␤ were 0.93 and 4.1 pM, respectively. (C) Effects of pertussis toxin on the I-BOPinduced inhibition of forskolin-induced cAMP accumulation. Cells were cultured in the presence (ϩ) or absence (Ϫ) of pertussis toxin (PT) for 12 h, then incubated with 1 M forskolin and 100 pM I-BOP and the cAMP contents were determined. Data points are meanϮSE from six replicate wells from a single experiment. The results were independently confirmed in two additional experiments. ity to desensitization (40) . The present study suggests that the carboxyl-terminal tails of the two TXA 2 receptor isoforms, like those of the bovine EP 3 receptor (39), determine the specificity of G protein coupling. Furthermore, the distinctive effects of the Arg 60 to Leu mutation suggested that the interaction of the receptor with different G proteins is distinctly regulated by different domains of the receptor; this residue appears to be important for the interaction of the receptor with G q and possibly with G s , but not with G i /G o .
Taken together, the data presented here support the existence of multiple signaling pathways via the two TXA 2 receptor isoforms in platelets, which could interact each other to coordinate platelet activation processes. Comparison of the effects of the Arg 60 to Leu mutation on these pathways with the responses observed in the platelets of the patients with this mutation implicates the possible relationship between the TXR␤-G i pathway and the platelet shape change and PLA 2 activation. This hypothesis should be rigorously tested in future studies.
